演題抄録

International Session(Poster)

開催概要
開催回
第51回・2013年・京都
 

The assessment of Formoterol Sting treatment of non-small cell lung cancer

演題番号 : ISP-23

[筆頭演者]
Chunyi Jia:1 
[共同演者]
Qiwen Wang:1

1:Tumor Hospital of Jilin Province, China

 

Abstract: Objective To observe the efficacy of treatment of 60 cases of non-small cell lung cancer with brain metastasis situation and the security of the Fotemustine and Nimustine. Methods: Fotemustine: in accordance with the body surface area will be a certain amount of a drug administered to a patient, induction period: A group to fotemustine 100mg/m2 IV, D1, D8, D15, 4-5 weeks of withdrawal; sustain period: fotemustine 100mg/m2 iv d1, d21, repeated maintenance treatment after three weeks of rest, and then carry out the evaluation of efficacy and safety. Group B reference Nimustine chemotherapy drug manual chemotherapy. Week follow-up blood count, liver function and renal function during treatment. In all cases two cycles of chemotherapy, followed by 4 weeks after review of brain CT or MRI, to observe changes in intracranial lesions. The results: the treatment effect: Fotemustine group CR + PR 66.7%, Nimustine group CR + PR 60.0%, P = 0.592 There was no statistically significant difference. Formoterol Sting group reflect the situation of the gastrointestinal tract 1 +2 level accounted for 83.3%, slightly lower than the nimodipine the Westin group 90% (P = 0.71) There was no significant difference. The Fotemustine myelosuppression 1+2 level accounted for 93.3%, higher than the Nimustine group 66.7% (P = 0.01), the two groups statistically significant difference. Conclusion: Fotemustine intravenous chemotherapy for non-small cell lung cancer with brain metastasis safe and effective.Keywords: non-small cell lung cancer; brain metastases; chemotherapy; Fotemustine; Nimustine; efficacy; safety

前へ戻る